drugset / Trial / NCT01240980
Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability and effect on blood glucose control of BMS-903452 compared to placebo in healthy subjects \& relative bioavailability of the crystalline and amorphous forms of BMS-903452 \[Panels 4,6,11 \& 12(Part A)\] ; and subjects with type 2 Diabetes Mellitus (Part B). The study will also determine the amount of BMS-903452 in the blood.
Timeline
- Start
- 2010-11
- Primary completion
- 2012-01
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-903452 | Small molecule | 0.1 mg | Oral |
| Subject | BMS-903452 | Small molecule | 0.6 mg | Oral |
| Subject | BMS-903452 | Small molecule | 3 mg | Oral |
| Subject | BMS-903452 | Small molecule | 10 mg | Oral |
| Subject | BMS-903452 | Small molecule | 30 mg | Oral |
| Subject | BMS-903452 | Small molecule | 60 mg | Oral |
| Subject | BMS-903452 | Small molecule | 120 mg | Oral |